- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07232069
Évaluation et Prise en Charge Prospective Randomisée de l'Athérosclérose Prématurée (PRE-EMPT) (PRE-EMPT)
Évaluation et Gestion Prospératives Randomisées de l'Athérosclérose Prématurée
Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States. This clinical trial will test if screening and early treatment of mild heart disease works.
PRE-EMPT will screen individuals at low 10-year risk of heart disease with heart disease risk factors to identify those who already have early cholesterol build up, also called "plaque", in their heart arteries. It consists of two phases:
-
A Screening Study - Participants will be assessed for plaque by one or both of these scans.
- Coronary Artery Calcium (CAC) Scan: A CT scan that looks for calcium or plaque in heart arteries.
- Coronary CT Angiography (CCTA) Scan: A CT scan that uses contrast dye to create detailed 3D pictures of heart arteries to look for plaque.
-
A Treatment Trial (approximately 1,500 participants) - Based on the results of the CCTA, participants may be randomized into a two-year trial to test medications aimed at reducing or stabilizing plaque. Participants will have a 1 in 4 chance of receiving only placebo, and a 3 in 4 chance of receiving at least one active medication. Participants will take two pills once a day-either both active medications, one active and one placebo, or both placebos.
- Rosuvastatin 20 mg: a cholesterol-lowering medicine
- Colchicine 0.5 mg: a medication that lowers inflammation
Everyone in the trial will be given information and advice on heart-healthy diet and lifestyle.
Participants will have up to two in-person visits for the screening study, then phone visits for the Treatment Trial at the beginning, 3 months, 12 months and 24 months when they will also have an in-person visit for a CCTA Scan. Participants will have blood drawn using an at-home collection device mailed to their home at the beginning, 3 months, and end of the study.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
The PRE-EMPT trial will be a 2x2 factorial, double-masked, placebo-controlled randomized trial of the effects of high-intensity statin and low-dose colchicine, alone and in combination, on CCTA-defined Non-Calcified Coronary Plaque (NCCP) volume at 2 years. Participants found through the screening study with CAC 1-99, or through the known plaque pathway, will be eligible for the trial if they have NCCP without severe stenosis or any other exclusion criteria. Study drug will be delivered directly to participants' homes, lab samples will be self-collected at home, and all study visits will be virtual except the imaging visits (up to 3 over 2 years). The only in-person study activities will be the CAC scan, if applicable, and CCTA at baseline and 2 years. The investigators anticipate that this approach will be attractive to middle-aged, busy individuals who are otherwise healthy and asymptomatic. Importantly, all participants in PRE-EMPT will receive an mHealth lifestyle intervention designed to support behavioral modification, ensuring that all individuals benefit from evidence-based strategies for cardiovascular risk reduction.
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: Rachel Olson, Project Manager
- Numéro de téléphone: 919-309-5544
- E-mail: rachel.e.olson@duke.edu
Lieux d'étude
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35205
- Recrutement
- University of Alabama at Birmingham
-
Chercheur principal:
- Kevin Riggs, MD
-
Contact:
- Dalton Norwood
- Numéro de téléphone: 909-786-8315
- E-mail: daltonnorwood@uabmc.edu
-
Mobile, Alabama, États-Unis, 36608
- Recrutement
- Cardiology Associates
-
Contact:
- Lynn Ward, RN BSN CCRC
- Numéro de téléphone: 251-607-9797
- E-mail: lynnward@cardassoc.com
-
Chercheur principal:
- Jason Cole, MD
-
-
California
-
Los Angeles, California, États-Unis, 90095
- Recrutement
- University of California, Los Angeles
-
Contact:
- Lynae Edmunds
- Numéro de téléphone: 310--210-9806
- E-mail: laedmunds@mednet.ucla.edu
-
Chercheur principal:
- Karol Watson, MD
-
Los Angeles, California, États-Unis, 90502
- Recrutement
- Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center
-
Contact:
- Sajad Hamal
- Numéro de téléphone: 310-974-9336
- E-mail: shamal@lundquist.org
-
Chercheur principal:
- Matthew Budoff, MD
-
-
Georgia
-
Hiram, Georgia, États-Unis, 30141
- Recrutement
- Wellstar Kennestone Hospital
-
Chercheur principal:
- Frank Corrigan, MD
-
Contact:
- Frank Corrigan, MD
- Numéro de téléphone: 678-324-4444
- E-mail: frank.corrigan@wellstar.org
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60637
- Recrutement
- University of Chicago
-
Chercheur principal:
- Tamar Polonsky, MD
-
Contact:
- Tamar Polonsky, MD
- Numéro de téléphone: 773-702-1409
- E-mail: tpolonsky@bsd.uchicago.edu
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21287
- Pas encore de recrutement
- Johns Hopkins University
-
Contact:
- Prati Pratishruti, MBBS
- Numéro de téléphone: 410-301-1245
- E-mail: fpratis1@jhu.edu
-
Chercheur principal:
- Michael Blaha, MD
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02114
- Recrutement
- Massachusetts General Hospital Brigham
-
Contact:
- Pearl Lee, MSc
- Numéro de téléphone: 617-721-7783
- E-mail: plee23@mgh.harvard.edu
-
Chercheur principal:
- Michael Honigberg, MD
-
-
Minnesota
-
Duluth, Minnesota, États-Unis, 55805
- Recrutement
- Essentia Health
-
Contact:
- Martha Vanderlinde, BS
- Numéro de téléphone: 218-786-2729
- E-mail: Martha.Vanderlinde@essentiahealth.org
-
Chercheur principal:
- Catherine Benzinger, MD
-
-
New York
-
Mount Kisco, New York, États-Unis, 10549
- Pas encore de recrutement
- Northern Westchester Hospital
-
Contact:
- Dina Katz, MD
- Numéro de téléphone: 914-762-5810
- E-mail: PRE-EMPT@northwell.edu
-
Chercheur principal:
- Dina Katz, MD
-
New York, New York, États-Unis, 10021
- Recrutement
- Weill Cornell Medicine
-
Contact:
- Dolores Reynolds, RN
- Numéro de téléphone: 212-746-4617
- E-mail: dtr2001@med.cornell.edu
-
Chercheur principal:
- Sam Kim, MD
-
New York, New York, États-Unis, 10016
- Recrutement
- New York University Langone
-
Chercheur principal:
- Harmony Reynolds, MD
-
Contact:
- Harmony Reynolds, MD
- Numéro de téléphone: 212-263-4320
- E-mail: PREEMPT@nyulangone.org
-
-
North Carolina
-
Durham, North Carolina, États-Unis, 27710
- Recrutement
- Duke University Hospital
-
Chercheur principal:
- Nishant Shah, MD
-
Contact:
- Niki Huffman
- Numéro de téléphone: 919-681-6458
- E-mail: niki.huffman@duke.edu
-
Winston-Salem, North Carolina, États-Unis, 27157
- Recrutement
- Wake Forest University, Advocate Health
-
Chercheur principal:
- Michael Shapiro, MD
-
Contact:
- Sophia Dawson, BA
- Numéro de téléphone: 336-713-2338
- E-mail: Sophia.Dawson@advocatehealth.org
-
-
Oregon
-
Portland, Oregon, États-Unis, 97239
- Pas encore de recrutement
- Oregon Health and Sciences University
-
Contact:
- John Halvorson
- Numéro de téléphone: 503-418-1679
- E-mail: halvorsj@ohsu.edu
-
Chercheur principal:
- Maros Ferencik, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19107
- Pas encore de recrutement
- Thomas Jefferson University
-
Contact:
- Caroline Freeman, BS
- Numéro de téléphone: 215-792-3872
- E-mail: Caroline.Freeman@Jefferson.edu
-
Chercheur principal:
- Chris Chambers, MD
-
Pittsburgh, Pennsylvania, États-Unis, 15213
- Recrutement
- University of Pittsburgh Medical Center
-
Chercheur principal:
- Anum Saeed, MD
-
Contact:
- Karli Drewencki
- Numéro de téléphone: 412-647-2931
- E-mail: drewenckikr2@upmc.edu
-
-
South Carolina
-
Charleston, South Carolina, États-Unis, 29425
- Recrutement
- Medical University of South Carolina (MUSC)
-
Chercheur principal:
- Sheldon Litwin, MD
-
Contact:
- Melissa Amitrano, MPH
- Numéro de téléphone: 843-876-5009
- E-mail: amitrano@musc.edu
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37203
- Pas encore de recrutement
- Vanderbilt University
-
Chercheur principal:
- Deepak Gupta, MD
-
Contact:
- Gabriella Davies Thoppil, MD MPH
- Numéro de téléphone: 615-421-1143
- E-mail: g.thoppil@vumc.org
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- Recrutement
- Houston Methodist Hospital
-
Contact:
- Peyton Martin
- Numéro de téléphone: 443-413-6350
- E-mail: knasir@houstonmethodist.org
-
Chercheur principal:
- Khurrrram Nasir, MD
-
-
Virginia
-
Charlottesville, Virginia, États-Unis, 22903
- Recrutement
- University of Virginia (UVA)
-
Contact:
- James Ingersoll
- Numéro de téléphone: 434-982-1058
- E-mail: WFC5KC@uvahealth.org
-
Chercheur principal:
- Todd Villines, MD
-
Fairfax, Virginia, États-Unis, 22031
- Pas encore de recrutement
- Inova Health System
-
Contact:
- Mahira Awan
- Numéro de téléphone: 571-472-8570
- E-mail: mahira.awan@inova.org
-
Chercheur principal:
- Jared Spitz, MD
-
-
Wisconsin
-
Marshfield, Wisconsin, États-Unis, 54449
- Recrutement
- Marshfield Clinical Research Institute
-
Contact:
- Kelly Scheffen
- Numéro de téléphone: 715-221-7285
- E-mail: preempt@marshfieldresearch.org
-
Chercheur principal:
- Jeff VanWormer
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Women aged 40-60 years; Men aged 30-50 years
- Willing and able to provide informed consent and comply with study procedures
- Smart phone user
- Use of highly effective contraception by females with reproductive potential.
- CAC score 1-99 in the screening study or entry through the known plaque pathway (with mild CAC or CAC<100 if known; elevated CAC on baseline CCTA is not exclusionary in the known plaque arm)
- Diagnostic baseline CCTA with NCPV ≥10 mm3 as assessed by the central core lab
Exclusion Criteria:
- Clinical diagnosis of ASCVD including coronary artery disease (CAD), peripheral arterial disease (PAD) or cerebrovascular disease (CeVD)
- Current symptoms thought to be from CAD
- PREVENT ASCVD 10-year risk ≥5% (if known)
- Diabetes Mellitus (DM) as defined by any of the following: DM diagnosis in the medical record or HbA1C of 6.5% or greater. (if known)
- LDL-C ≥190mg/dL (most recent, if known)
- HIV (if known)
- Severe liver disease or untreated Hepatitis C infection (if known)
- Pregnancy, lactation or intending to become pregnant during the study period of 2 years
- eGFR <45mL/min/1.73m2 (if known)
- AST or ALT >1.5x the upper limit of normal (if known)
- BMI>40kg/m2 or unable to have a CCTA scan for any reason
- Allergy to iodinated intravenous contrast or other contraindication to CCTA
- Current or previous use of lipid lowering therapy or colchicine
- Known allergic reactions or sensitivity to the study intervention(s), including known intolerance or contraindication(s) to statin or colchicine, or long-term use of medications that are contraindicated with colchicine or rosuvastatin.
- Systemic cancer undergoing active treatment
- PREVENT ASCVD 10-year risk ≥5%
- eGFR <45 ml/min/1.73m2 per baseline labs, (2021 CKD-EPI equation will be used if multiple options are available)
- Hemoglobin A1c ≥6.5% per baseline labs
- LDL-C ≥190mg/dL per baseline labs
- Severe proximal coronary artery stenosis as determined by the central core lab (≥50% left main or ≥70% proximal major coronary artery stenosis)
- Known contraindication to follow-up CCTA (e.g., new IV contrast allergy discovered during the baseline CCTA)
- Individuals who are excluded based on any of these factors will be notified as to the reason for exclusion and encouraged to follow-up locally to address this medical issue with their treating physician.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation factorielle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: rosuvastatin 20mg plus colchicine-matched placebo
statin plus placebo (two pills once daily) |
Statin
Autres noms:
Placebo, non-active, drug-matched |
|
Expérimental: colchicine 0.5mg plus rosuvastatin-matched placebo
anti-inflammatory plus placebo (two pills once daily) |
Placebo, non-active, drug-matched Anti-inflammatory
Autres noms:
|
|
Expérimental: rosuvastatin 20mg plus colchicine 0.5mg
statin plus anti-inflammatory (two pills once daily) |
Statin
Autres noms:
Anti-inflammatory
Autres noms:
|
|
Comparateur placebo: placebo plus placebo
Placebo and placebo (two pills once daily) |
Placebo, non-active, drug-matched |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Non-calcified plaque volume (NCPV) on CCTA at 2 years, adjusted for baseline NCPV.
Délai: 2 years
|
Plaque volume in mm3 in each group |
2 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Changement du LDL-C (lipoprotéine de basse densité cholestérol)
Délai: De la ligne de base à 2 ans
|
De la ligne de base à 2 ans
|
|
|
Changement du cholestérol non-HDL (cholestérol non-lipoprotéines de haute densité)
Délai: De la ligne de base à 2 ans
|
De la ligne de base à 2 ans
|
|
|
Number of participants with Drug Discontinuation
Délai: Up to 2 years
|
Drug Tolerability outcome |
Up to 2 years
|
|
Overall drug treatment adherence
Délai: Up to 2 years
|
Number of days on study drugs |
Up to 2 years
|
|
Safety events of special interest
Délai: Up to 2 years
|
Number of safety events of special interest per group |
Up to 2 years
|
|
Total plaque volume
Délai: Up to 2 years
|
Plaque volume in mm3 per group |
Up to 2 years
|
|
Low-attenuation plaque volume
Délai: Up to 2 years
|
Low attenuated plaque volume in mm3 per group |
Up to 2 years
|
|
Calcified plaque volume
Délai: Up to 2 years
|
Calcified plaque volume in mm3 per group |
Up to 2 years
|
|
Number of participants with stenosis
Délai: Up to 2 years
|
Number of participants with stenosis per group |
Up to 2 years
|
|
Segment involvement score
Délai: Up to 2 years
|
Average score per group |
Up to 2 years
|
|
Number of participants with qualitative calcified, partially calcified and non-calcified plaque composition
Délai: Up to 2 years
|
Number of participants with each plaque composition description per group |
Up to 2 years
|
|
Number of participants with High-risk plaque features (positive remodeling, spotty calcium, napkin ring sign)
Délai: Up to 2 years
|
Number of participants with each plaque feature (high-risk) per group |
Up to 2 years
|
Collaborateurs et enquêteurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Composés de soufre
- Produits chimiques organiques
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Préparations pharmaceutiques
- Formulaires de dosage
- Hydrocarbures
- Alcaloïdes
- Amides
- Pyrimidines
- Hydrocarbures, halogénés
- Sulfonamides
- Sulfones
- Fluorobenzènes
- Hydrocarbures, fluorés
- Rosuvastatine calcique
- Colchicine
- Comprimés
Autres numéros d'identification d'étude
- Pro00118744
- UG3HL181434 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .